Here’s What’s Behind The Hottest Battleground Stock in Cancer Treatment
CEL-SCI (NYSEMKT: CVM) is arguably the most intense battleground stock the biotech oncology sector has ever witnessed. On the bullish side, investors have dedicated an entire website calling for the figurative annihilation of short-sellers of the company's stock. On the other hand, those betting against CEL-SCI have called the company "One of the biggest scams of the 21st century."
Meanwhile, phase 3 topline results from the company's only prominent candidate, Multikine (leukocyte injection for the treatment of cancer in the oral cavity and soft palate), is set to be released in May. The company's fate is entirely dependent on the success of Multikine, as it is currently pre-revenue and has little cash on hand to fund further expenses.
If it becomes approved, the drug has a total addressable market of over $2 billion in the U.S. alone, as it treats a subset of head and neck cancer. Moreover, CEL-SCI has a partnership with Teva Pharmaceutical Industries (NYSE: TEVA) to commercialize the drug worldwide upon approval. Just what exactly is causing so much controversy for a company developing an innovative method to combat cancer? Let's find out.
Source Fool.com
